Dmannvbs · Newsroom
Vascular BioSciences Publishes "CAR Selectively Enhances the Pulmonary Vasodilatory Effect of Fasudil in a Model of Pulmonary Hypertension"
Novel homing peptide enables targeted therapies for pulmonary hypertensionDecember 31, 2023
Vascular BioSciences Publishes “A Bioinformatic Algorithm based on Pulmonary Endoarterial Biopsy for Targeted Pulmonary Arterial Hypertension Therapy”
Pioneering approach opens new doors for targeted pulmonary arterial hypertension therapyDecember 31, 2023
Vascular BioSciences Announces New Preclinical Research Results Demonstrating Improved Pulmonary Hypertension and Sepsis Survival with CAR Peptide
CEO of Vascular BioSciences, David Mann, makes connection between current research and COVID-19 applicationsJune 4, 2020
FDA Grants Vascular BioSciences HUD Designation to the Endoarterial Biopsy Catheter for Group 1 PAH
VBS received HUD designation from FDA for EABx Catheter to take pulmonary artery biopsies in PAH patients.September 6, 2019
Vascular BioSciences Awarded $2 Million Phase II STTR Grant From NHLBI
Grant awarded in partnership with Brigham and Women’s Hospital, Harvard Medical School to develop CAR peptide as a targeted therapy for pulmonary hypertensionOctober 19, 2018